These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

277 related items for PubMed ID: 34425216

  • 1. Dual SMN inducing therapies can rescue survival and motor unit function in symptomatic ∆7SMA mice.
    Kray KM, McGovern VL, Chugh D, Arnold WD, Burghes AHM.
    Neurobiol Dis; 2021 Nov; 159():105488. PubMed ID: 34425216
    [Abstract] [Full Text] [Related]

  • 2. ZPR1 prevents R-loop accumulation, upregulates SMN2 expression and rescues spinal muscular atrophy.
    Kannan A, Jiang X, He L, Ahmad S, Gangwani L.
    Brain; 2020 Jan 01; 143(1):69-93. PubMed ID: 31828288
    [Abstract] [Full Text] [Related]

  • 3. Combinatorial ASO-mediated therapy with low dose SMN and the protective modifier Chp1 is not sufficient to ameliorate SMA pathology hallmarks.
    Muinos-Bühl A, Rombo R, Janzen E, Ling KK, Hupperich K, Rigo F, Bennett CF, Wirth B.
    Neurobiol Dis; 2022 Sep 01; 171():105795. PubMed ID: 35724821
    [Abstract] [Full Text] [Related]

  • 4. Antisense Oligonucleotide Induction of the hnRNPA1b Isoform Affects Pre-mRNA Splicing of SMN2 in SMA Type I Fibroblasts.
    Toosaranont J, Ruschadaariyachat S, Mujchariyakul W, Arora JK, Charoensawan V, Suktitipat B, Palmer TN, Fletcher S, Wilton SD, Mitrpant C.
    Int J Mol Sci; 2022 Apr 01; 23(7):. PubMed ID: 35409296
    [Abstract] [Full Text] [Related]

  • 5. The oral splicing modifier RG7800 increases full length survival of motor neuron 2 mRNA and survival of motor neuron protein: Results from trials in healthy adults and patients with spinal muscular atrophy.
    Kletzl H, Marquet A, Günther A, Tang W, Heuberger J, Groeneveld GJ, Birkhoff W, Mercuri E, Lochmüller H, Wood C, Fischer D, Gerlach I, Heinig K, Bugawan T, Dziadek S, Kinch R, Czech C, Khwaja O.
    Neuromuscul Disord; 2019 Jan 01; 29(1):21-29. PubMed ID: 30553700
    [Abstract] [Full Text] [Related]

  • 6. A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse.
    Porensky PN, Mitrpant C, McGovern VL, Bevan AK, Foust KD, Kaspar BK, Wilton SD, Burghes AH.
    Hum Mol Genet; 2012 Apr 01; 21(7):1625-38. PubMed ID: 22186025
    [Abstract] [Full Text] [Related]

  • 7. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice.
    Torres-Benito L, Schneider S, Rombo R, Ling KK, Grysko V, Upadhyay A, Kononenko NL, Rigo F, Bennett CF, Wirth B.
    Am J Hum Genet; 2019 Jul 03; 105(1):221-230. PubMed ID: 31230718
    [Abstract] [Full Text] [Related]

  • 8. Normalization of Patient-Identified Plasma Biomarkers in SMNΔ7 Mice following Postnatal SMN Restoration.
    Arnold WD, Duque S, Iyer CC, Zaworski P, McGovern VL, Taylor SJ, von Herrmann KM, Kobayashi DT, Chen KS, Kolb SJ, Paushkin SV, Burghes AH.
    PLoS One; 2016 Jul 03; 11(12):e0167077. PubMed ID: 27907033
    [Abstract] [Full Text] [Related]

  • 9. Nusinersen ameliorates motor function and prevents motoneuron Cajal body disassembly and abnormal poly(A) RNA distribution in a SMA mouse model.
    Berciano MT, Puente-Bedia A, Medina-Samamé A, Rodríguez-Rey JC, Calderó J, Lafarga M, Tapia O.
    Sci Rep; 2020 Jul 01; 10(1):10738. PubMed ID: 32612161
    [Abstract] [Full Text] [Related]

  • 10. Motor transmission defects with sex differences in a new mouse model of mild spinal muscular atrophy.
    Deguise MO, De Repentigny Y, Tierney A, Beauvais A, Michaud J, Chehade L, Thabet M, Paul B, Reilly A, Gagnon S, Renaud JM, Kothary R.
    EBioMedicine; 2020 May 01; 55():102750. PubMed ID: 32339936
    [Abstract] [Full Text] [Related]

  • 11. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape.
    Wood MJA, Talbot K, Bowerman M.
    Hum Mol Genet; 2017 Oct 01; 26(R2):R151-R159. PubMed ID: 28977438
    [Abstract] [Full Text] [Related]

  • 12. Oligonucleotide-mediated survival of motor neuron protein expression in CNS improves phenotype in a mouse model of spinal muscular atrophy.
    Williams JH, Schray RC, Patterson CA, Ayitey SO, Tallent MK, Lutz GJ.
    J Neurosci; 2009 Jun 17; 29(24):7633-8. PubMed ID: 19535574
    [Abstract] [Full Text] [Related]

  • 13. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model.
    Hua Y, Sahashi K, Rigo F, Hung G, Horev G, Bennett CF, Krainer AR.
    Nature; 2011 Oct 05; 478(7367):123-6. PubMed ID: 21979052
    [Abstract] [Full Text] [Related]

  • 14. Plastin 3 Expression Does Not Modify Spinal Muscular Atrophy Severity in the ∆7 SMA Mouse.
    McGovern VL, Massoni-Laporte A, Wang X, Le TT, Le HT, Beattie CE, Rich MM, Burghes AH.
    PLoS One; 2015 Oct 05; 10(7):e0132364. PubMed ID: 26134627
    [Abstract] [Full Text] [Related]

  • 15. CHP1 reduction ameliorates spinal muscular atrophy pathology by restoring calcineurin activity and endocytosis.
    Janzen E, Mendoza-Ferreira N, Hosseinibarkooie S, Schneider S, Hupperich K, Tschanz T, Grysko V, Riessland M, Hammerschmidt M, Rigo F, Bennett CF, Kye MJ, Torres-Benito L, Wirth B.
    Brain; 2018 Aug 01; 141(8):2343-2361. PubMed ID: 29961886
    [Abstract] [Full Text] [Related]

  • 16. Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy.
    Zhou H, Meng J, Malerba A, Catapano F, Sintusek P, Jarmin S, Feng L, Lu-Nguyen N, Sun L, Mariot V, Dumonceaux J, Morgan JE, Gissen P, Dickson G, Muntoni F.
    J Cachexia Sarcopenia Muscle; 2020 Jun 01; 11(3):768-782. PubMed ID: 32031328
    [Abstract] [Full Text] [Related]

  • 17. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
    Pagliarini V, Guerra M, Di Rosa V, Compagnucci C, Sette C.
    J Neurochem; 2020 Apr 01; 153(2):264-275. PubMed ID: 31811660
    [Abstract] [Full Text] [Related]

  • 18. SMN expression is required in motor neurons to rescue electrophysiological deficits in the SMNΔ7 mouse model of SMA.
    McGovern VL, Iyer CC, Arnold WD, Gombash SE, Zaworski PG, Blatnik AJ, Foust KD, Burghes AH.
    Hum Mol Genet; 2015 Oct 01; 24(19):5524-41. PubMed ID: 26206889
    [Abstract] [Full Text] [Related]

  • 19. Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy.
    Paton DM.
    Drugs Today (Barc); 2017 Jun 01; 53(6):327-337. PubMed ID: 28799578
    [Abstract] [Full Text] [Related]

  • 20. SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN.
    Le TT, Pham LT, Butchbach ME, Zhang HL, Monani UR, Coovert DD, Gavrilina TO, Xing L, Bassell GJ, Burghes AH.
    Hum Mol Genet; 2005 Mar 15; 14(6):845-57. PubMed ID: 15703193
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.